Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer

Biology of the Cell

Volumn 107, Issue 7, 2015, Pages 232-244

  Alshalalfa, Mohammed ^a   Schliekelman, Mark ^a   Shin, Heesun ^a   Erho, Nicholas ^a   Davicioni, Elai ^a  

^a GenomeDx Biosciences Inc   (Canada)

Author keywords

Metastasis; Prostate; Radical prostatectomy; Transcriptomic fingerprint

Indexed keywords

TRANSCRIPTOME; TUMOR MARKER;

ADULT; AGED; BIOSYNTHESIS; CLINICAL TRIAL; EVALUATION STUDY; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSTATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TRANSCRIPTOME;

EID: 84934438672     PISSN: 02484900     EISSN: 1768322X     Source Type: Journal    
DOI: 10.1111/boc.201400097     Document Type: Article

References (63)

1. Alshalalfa, M., Crisan, A., Vergara, I.A., Ghadessi, M., Buerki, C., Erho, N. and Yousefi, K. (2015) Clinical and genomic analysis of metastatic prostate cancer progression in a background of post-operative biochemical recurrence. BJU Int. doi:10.1111/bju13013.
2. Badani, K., Thompson, D.J.S., Buerki, C., Davicioni, E., Garrison, J., Ghadessi, M., Mitra, A.P., Wood, P.J. and Hornberger, J. (2013) Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget 4, 600-609
3. Barbieri, C.E., Bangma, C.H., Bjartell, A., Catto, J.W.F., Culig, Z., Grönberg, H., Luo, J., Visakorpi, T. and Rubin, M.A. (2013) The mutational landscape of prostate cancer. Eur. Urol. 64, 567-576
4. Berger, M.F., Lawrence, M.S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A.Y., Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., Onofrio, R., Carter, S.L., Park, K., Habegger, L., Ambrogio, L., Fennell, T., Parkin, M., Saksena, G., Voet, D., Ramos, A.H., Pugh, T.J., Wilkinson, J., Fisher, S., Winckler, W., Mahan, S., Ardlie, K., Baldwin, J., Simons, J.W., Kitabayashi, N., MacDonald, T.Y., Kantoff, P.W., Chin, L., Gabriel, S.B., Gerstein, M.B., Golub, T.R., Meyerson, M., Tewari, A., Lander, E.S., Getz, G., Rubin, M.A., Garraway, L.A. (2011) The genomic complexity of primary human prostate cancer. Nature 470, 214-220
5. Bismar, T.A., Alshalalfa, M., Petersen, L.F., Teng, L.H., Gerke, T., Bakkar, A., Al-Mami, A., Liu, S., Dolph, M., Mucci, L.A., Alhajj, R. (2014) Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. BJU Int. 113, 309-319
6. Boorjian, S.A., Thompson, R.H., Tollefson, M.K., Rangel, L.J., Bergstralh, E.J., Blute, M.L. and Karnes, R.J. (2011) Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur. Urol. 59, 893-899
7. Boormans, J.L., Korsten, H., Ziel-Van Der Made, A.J.C., Van Leenders, G.J.L.H., De Vos, C.V., Jenster, G. and Trapman, J. (2013) Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. Int. J. Cancer 133, 335-345
8. Boyd, L.K., Mao, X. and Lu, Y.-J. (2012) The complexity of prostate cancer: genomic alterations and heterogeneity. Nat. Rev. Urol. 9, 652-664
9. Brase, J.C., Johannes, M., Mannsperger, H., Falth, M., Metzger, J., Kacprzyk, L.A., Andrasiuk, T., Gade, S., Meister, M., Sirma, H., Sauter, G., Simon, R., Schlomm, T., Beissbarth, T., Korf, U., Kuner, R., Sultmann, H. (2011) TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 11, 507. doi:10.1186/1471-2407-11-507
10. Chakravarty, D., Sboner, A., Nair, S.S., Giannopoulou, E., Li, R., Hennig, S., Mosquera, J.M. and Pauwels, J. (2014) The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat. Commun. 5, 5383
11. Chen, Z., Zhang, C., Wu, D., Chen, H., Rorick, A., Zhang, X. and Wang, Q. (2011) Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 30, 2405-2419
12. Cheng, W., Zhang, Z. and Wang, J. (2013) Long noncoding RNAs: New players in prostate cancer. Cancer Lett. 339, 8-14
13. Cooperberg, M.R., Davicioni, E., Crisan, A., Jenkins, R.B., Ghadessi, M. and Karnes, R.J. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur. Urol. 67, 326-333
14. Crea, F., Watahiki, A., Quagliata, L., Xue, H., Pikor, L., Parolia, A., Wang, Y., Lin, D., Lam, W.L., Farrar, W.L., Isogai, T., Morant, R., Castori-Eppenberger, S., Chi, K.N., Wang, Y., Helgason, C.D., (2014) Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 5, 764-774
15. Cuzick, J., Swanson, G.P., Fisher, G., Brothman, A.R., Berney, D.M., Reid, J.E., Mesher, D., Speights, V.O., Stankiewicz, E., Foster, C.S., Møller, H., Scardino, P., Warren, J.D., Park, J., Younus, A., Flake, D.D., Wagner, S., Gutin, A., Lanchbury, J.S., Stone, S., (2011) Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol. 12, 245-255
16. Cuzick, J., Berney, D.M., Fisher, G., Mesher, D., Møller, H., Reid, J.E., Perry, M., Park, J., Younus, A., Gutin, A., Foster, C.S., Scardino, P., Lanchbury, J.S., Stone, S., (2012) Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br. J. Cancer 106, 1095-1099
17. Davis, J. (2014) Novel commercially available genomic tests for prostate cancer: a roadmap to understanding their clinical impact. BJU Int. 114, 320-322
18. Den, R.B., Feng, F.Y., Showalter, T.N., Mishra, M. V., Trabulsi, E.J., Lallas, C.D., Gomella, L.G., Kelly, W.K., Birbe, R.C., McCue, P.A., Ghadessi, M., Yousefi, K., Davicioni, E., Knudsen, K.E., Dicker, A.P. (2014) Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. Int. J. Radiat. Oncol. 89, 1038-1046
19. Dennis, G., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C. and Lempicki, R.A. (2003) DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol. 4, P3
20. Dooley, A.L., Winslow, M.M., Chiang, D.Y., Banerji, S., Stransky, N., Dayton, T.L., Snyder, E.L., Senna, S., Whittaker, C.A., Bronson, R.T., Crowley, D., Barretina, J., Garraway, L., Meyerson, M., Jacks, T., (2011) Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev. 25, 1470-1475
21. TM PCA3 test for prostate cancer. Expert Rev. Mol. Diagn. 11, 137-144
22. Erho, N., Crisan, A., Vergara, I.A., Mitra, A.P., Ghadessi, M., Buerki, C., Bergstralh, E.J., Kollmeyer, T., Fink, S., Haddad, Z., Zimmermann, B., Sierocinski, T., Ballman, K. V, Triche, T.J., Black, P.C., Karnes, R.J., Klee, G., Davicioni, E., Jenkins, R.B., (2013) Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One 8, e66855
23. Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., Jensen, L.J., (2013) STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808-D815
24. Frietsch, J.J., Grunewald, T.G.P., Jasper, S., Kammerer, U., Herterich, S., Kapp, M., Honig, A. and Butt, E. (2010) Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer. Br. J. Cancer 102, 1645-1653
25. Fristrup, N., Birkenkamp-Demtrder, K., Reinert, T., Sanchez-Carbayo, M., Segersten, U., Malmstrm, P.U., Palou, J., Alvarez-Múgica, M., Pan, C.C., Ulhi, B.P., Borre, M., Rntoft, T.F., Dyrskjt, L., (2013) Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am. J. Pathol. 182, 339-349
26. Grunewald, T.G.P., Kammerer, U., Winkler, C., Schindler, D., Sickmann, A., Honig, A. and Butt, E. (2007) Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br. J. Cancer 96, 296-305
27. Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: The next generation. Cell 144, 646-674
28. Hessels, D. and Schalken, J.A. (2009) The use of PCA3 in the diagnosis of prostate cancer. Nat. Rev. Urol. 6, 255-261
29. Irshad, S., Bansal, M., Castillo-Martin, M., Zheng, T., Aytes, A., Wenske, S., LeMagnen, C., Guarnieri, P., Sumazin, P., Benson, M.C., Shen, M.M., Califano, A., Abate-Shen, C. (2013) A molecular signature predictive of indolent prostate cancer. Sci. Transl. Med. 5, 202ra122
30. Jiang, N., Zhu, S., Chen, J., Niu, Y. and Zhou, L. (2013) A-Methylacyl-CoA Racemase (AMACR) and prostate-cancer risk: A meta-analysis of 4, 385 participants. PLoS One 8, e74386
31. Jin, R., Yi, Y., Yull, F.E., Blackwell, T.S., Clark, P.E., Koyama, T., Smith, J. A. and Matusik, R.J. (2014) NF-κB gene signature predicts prostate cancer progression. Cancer Res. 74, 2763-2772
32. Karnes, R.J., Bergstralh, E., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A., Crisan, A., Erho, N., Vergara, I., Lam, L., Carlson, R., Thompson, D., Haddad, Z., Zimmermann, B., Sierocinski, T., Triche, T., Kollmeyer, T., Ballman, K., Black, P., Klee, G., Jenkins, R., (2013) Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J. Urol. 190, 2047-2053
33. Klein, E.A., Cooperberg, M.R., Magi-Galluzzi, C., Simko, J.P., Falzarano, S.M., Maddala, T., Chan, J.M., Li, J., Cowan, J.E., Tsiatis, A.C., Cherbavaz, D.B., Pelham, R.J., Tenggara-Hunter, I., Baehner, F.L., Knezevic, D., Febbo, P.G., Shak, S., Kattan, M.W., Lee, M., Carroll, P.R., (2014) A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur. Urol. 66, 550-560
34. Klein, E.A., Yousefi, K., Haddad, Z., Choeurng, V., Buerki, C., Stephenson, A.J., Li, J., Kattan, M.W., Magi-Galluzzi, C. and Davicioni, E. (2014b) A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur. Urol. 67, 778-786
35. Leyten, G.H.J.M., Hessels, D., Jannink, S.A., Smit, F.P., De Jong, H., Cornel, E.B., De Reijke, T.M., Vergunst, H., Kil, P., Knipscheer, B.C., Van Oort, I.M., Mulders, P.F.A., Hulsbergen-Van De Kaa, C.A., Schalken, J.A., (2014) Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur. Urol. 65, 534-542
36. Loussouarn, D., Campion, L., Leclair, F., Campone, M., Charbonnel, C., Ricolleau, G., Gouraud, W., Bataille, R. and Jézéquel, P. (2009) Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br. J. Cancer 101, 166-173
37. Markert, E.K., Mizuno, H., Vazquez, A. and Levine, A.J. (2011) Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. U.S.A. 108, 21276-21281
38. Martens-Uzunova, E.S., Böttcher, R., Croce, C.M., Jenster, G., Visakorpi, T. and Calin, G.A. (2014) Long noncoding RNA in prostate, bladder, and kidney cancer. Eur. Urol. 65, 1140-1151
39. Moon, H.G., Hwang, K.T., Kim, J.A., Kim, H.S., Lee, M.J., Jung, E.M., Ko, E., Han, W. and Noh, D.Y. (2011) NFIB is a potential target for estrogen receptor-negative breast cancers. Mol. Oncol. 5, 538-544
40. Mosakhani, N., Pazzaglia, L., Benassi, M.S., Borze, I., Quattrini, I., Picci, P. and Knuutila, S. (2012) MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone. Histol. Histopathol. 28, 671-678
41. Nakagawa, T., Kollmeyer, T.M., Morlan, B.W., Anderson, S.K., Bergstralh, E.J., Davis, B.J., Asmann, Y.W., Klee, G.G., Ballman, K.V. and Jenkins, R.B. (2008) A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One 3, e2318
42. Nwosu, V., Carpten, J., Trent, J.M. and Sheridan, R. (2001) Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum. Mol. Genet. 10, 2313-2318
43. Payne, H. and Cornford, P. (2011) Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol. Oncol. 29, 593-601
44. Penney, K.L., Sinnott, J.A., Fall, K., Pawitan, Y., Hoshida, Y., Kraft, P., Stark, J.R., Fiorentino, M., Perner, S., Finn, S., Calza, S., Flavin, R., Freedman, M.L., Setlur, S., Sesso, H.D., Andersson, S.-O., Martin, N., Kantoff, P.W., Johansson, J.-E., Adami, H.-O., Rubin, M.A., Loda, M., Golub, T.R., Andrén, O., Stampfer, M.J., Mucci, L.A., (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J. Clin. Oncol. 29, 2391-2396
45. Perdonà, S., Bruzzese, D., Ferro, M., Autorino, R., Marino, A., Mazzarella, C., Perruolo, G., Longo, M., Spinelli, R., Di Lorenzo, G., Oliva, A., De Sio, M., Damiano, R., Altieri, V., Terracciano, D., (2013) Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73, 227-235
46. Piccolo, S.R., Sun, Y., Campbell, J.D., Lenburg, M.E., Bild, A.H. and Johnson, W.E. (2012) A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 100, 337-344
47. Prensner, J.R. and Chinnaiyan, A.M. (2011) The emergence of lncRNAs in cancer biology. Cancer Discov. 1, 391-407
48. Prensner, J.R., Rubin, M.A., Wei, J.T. and Chinnaiyan, A.M. (2012) Beyond PSA: the next generation of prostate cancer biomarkers. Sci. Transl. Med. 4, 127rv3-rv127rv3
49. Prensner, J.R., Shuang, Z., Erho, N., Schipper, M., Lyer, M.K., Dhanasekaran, S.M. and Magi-Galluzzi, C. (2014) RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol. 15, 1469-1480
50. Psyrri, A., Kalogeras, K.T., Kronenwett, R., Wirtz, R.M., Batistatou, A., Bournakis, E., Timotheadou, E., Gogas, H., Aravantinos, G., Christodoulou, C., Makatsoris, T., Linardou, H., Pectasides, D., Pavlidis, N., Economopoulos, T., Fountzilas, G., (2012) Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) study. Ann. Oncol. 23, 1422-1427
51. Qiu, Y., Morii, E., Tomita, Y., Zhang, B., Matsumura, A., Kitaichi, M., Okumura, M. and Aozasa, K. (2009) Prognostic significance of pre B cell leukemia transcription factor 2 (PBX2) expression in non-small cell lung carcinoma. Cancer Sci. 100, 1198-1209
52. Ross, AE., Feng, F.Y., Ghadessi, M., Erho, N., Crisan, A., Buerki, C., Sundi, D., Mitra, A.P., Vergara, I.A., Thompson, D.J.S., Triche, T.J., Davicioni, E., Bergstralh, E.J., Jenkins, R.B., Karnes, R.J., Schaeffer, E.M. (2014) A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer Prostatic Dis. 17, 64-69
53. Ross, J.S., Hatzis, C., Symmans, W.F., Pusztai, L. and Hortob'agyi, G.N. (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 13, 477-493
54. Salami, S.S., Schmidt, F., Laxman, B., Regan, M.M., Rickman, D.S., Scherr, D., Bueti, G., Siddiqui, J., Tomlins, S.A., Wei, J.T., Chinnaiyan, A.M., Rubin, M.A., Sanda, M.G. (2013) Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol. Oncol. Semin. Orig. Investig. 31, 566-571
55. Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., Antipin, Y., Mitsiades, N., Landers, T., Dolgalev, I., Major, J.E., Wilson, M., Socci, N.D., Lash, A.E., Heguy, A., Eastham, J.A., Scher, H.I., Reuter, V.E., Scardino, P.T., Sander, C., Sawyers, C.L., and Gerald, W.L. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22
56. Tomlins, S.A., Aubin, S.M.J., Siddiqui, J., Lonigro, R.J., Sefton-Miller, L., Miick, S., Williamsen, S., Hodge, P., Meinke, J., Blase, A., Penabella, Y., Day, J.R., Varambally, R., Han, B., Wood, D., Wang, L., Sanda, M.G., Rubin, M.A., Rhodes, D.R., Hollenbeck, B., Sakamoto, K., Silberstein, J.L., Fradet, Y., Amberson, J.B., Meyers, S., Palanisamy, N., Rittenhouse, H., Wei, J.T., Groskopf, J., Chinnaiyan, A.M. (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Transl. Med. 3, 94ra72
57. Tosoian, J. and Loeb, S. (2010) PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Scientific World J. 10, 1919-1931
58. Traenka, C., Remke, M., Korshunov, A., Bender, S., Hielscher, T., Northcott, P.A., Witt, H., Ryzhova, M., Felsberg, J., Benner, A., Riester, S., Scheurlen, W., Grunewald, T.G.P., von Deimling, A., Kulozik, A.E., Reifenberger, G., Taylor, M.D., Lichter, P., Butt, E., Pfister, S.M. (2010) Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res. 70, 8003-8014
59. Trock, B.J., Brotzman, M., Mangold, L., Bigley, J., et al. (2012) Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. BJU Int. 110, 56-62
60. Weigelt, B., Peterse, J.L. and van 't Veer, L.J. (2005) Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602
61. Wu, C.-L., Schroeder, B.E., Ma, X.-J., Cutie, C.J., Wu, S., Salunga, R., Zhang, Y., Kattan, M.W., Schnabel, C.A., Erlander, M.G., McDougal, W.S. (2013) Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc. Natl. Acad. Sci. U.S.A. 110, 6121-6126
62. Wyatt, A.W., Mo, F., Wang, Y. and Collins, C.C. (2013) The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J. Androl. 15, 301-308
63. Yuan, Y., Van Allen, E.M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., Byers, L. a, Xu, Y., Hess, K.R., Diao, L., Han, L., Huang, X., Lawrence, M.S., Weinstein, J.N., Stuart, J.M., Mills, G.B., Garraway, L.A., Margolin, A.A., Getz, G., Liang, H. (2014) Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat. Biotechnol. 32, 644-652